IBX raises $5M in oversubscribed placement
29 July 2020 Highlights $5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly supported by existing domestic institutional investors and sophisticated…
La Trobe passes net zero solar milestone
27 July 2020 La Trobe University is destined to achieve net zero carbon emissions by 2029 with the completion of an ambitious solar energy project at its Bundoora Campus. The University has today energised 7500 solar panels on…
Community undersold in Australia’s response to COVID-19
27 July 2020 Burnet Institute Director and CEO Professor Brendan Crabb AC believes the critical importance of the community and community-informed research have been undersold in Australia’s response to the COVID-19 pandemic and need to be urgently prioritised.…
New drug blocks formation of killer clots to prevent strokes and heart attacks
27 July 2020 Monash researchers have found a potential drug that can be given as a preventive against heart attack and stroke. The drug – which has been studied in human cells and animal models – literally blocks…
New courses to transform digital healthcare
27 July 2020 A suite of new courses is set to equip health professionals with skills needed to keep pace with rapid technological advances in healthcare. RMIT Online and the Digital Health Cooperative Research Centre (CRC) have joined…
Gilead Sciences Announces The Appointment Of Ric Morgan As Head Of Legal And Compliance For Australia And New Zealand
23 July 2020 Gilead Sciences today announced the appointment of Ric Morgan as the new Head of Legal and Compliance ANZ for Gilead Sciences in Australia and New Zealand (ANZ). Mr Morgan joins Gilead Sciences ANZ with more…
First Participants Treated In AD-214 Phase I Clinical Trial
23 July 2020 AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that the first healthy participants in the blinded Phase I clinical trial of AD-214 have…
OMX Solutions Celebrate 200 Implantations of TMJ Joint Replacement Prosthesis
15 July 2020 Melbourne based design house for custom medical devices for oral and maxillofacial applications, OMX Solutions Pty Ltd is delighted to announce the 200th implantation of its custom designed temporomandibular joint (TMJ) replacement device, the OMX…
Global 3D printing partnership to boost local manufacturing
23 July 2020 RMIT University is partnering with Europe’s leading 3D printing institute to support the transformation of Australian manufacturing. The memorandum of understanding with Fraunhofer Institute for Material and Beam Technology IWS covers staff and student exchanges…
Crux Biolabs make Mountain Highway Business Park home
21 July 2020 This week Crux Biolabs is moving to a larger lab premises at the Mountain Highway Business Park in Bayswater. Crux’s growth since obtaining NATA accreditation to ISO 17025 in early 2019 has meant that…
UniQuest and CSL Limited partner to develop potential treatment for Sjogren’s Syndrome
20 July 2020 UniQuest, The University of Queensland’s (UQ’s) technology transfer company has announced it will partner with CSL to develop and commercialise UQ’s antigen specific immune tolerance induction (ASITI) technology for the treatment of Sjogren’s Syndrome. Under…
Noxopharm: Independent Data Confirms Idronoxil Achieves Major Industry Goal of Converting ‘COLD’ Tumours to ‘HOT’ Tumours
20 July 2020 Key points: Pre-clinical data indicates that idronoxil (active ingredient in Veyonda®) achieves major goal in converting immunologically ‘COLD’ tumours to ‘HOT’ ‘COLD’ to ‘HOT’ conversion restores cancer-fighting immune cells to tumours, seen as a prerequisite…
